Yahoo Finance • 4 days ago
SEATTLE and VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisiniclin... Full story
Yahoo Finance • 8 days ago
SEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisiniclin... Full story
Yahoo Finance • 14 days ago
* Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]) said that [https://seekingalpha.com/pr/20230175-achieve-life-sciences-names-dr-mark-rubinstein-interim-chief-medical-officer] Mark Rubinstein, M.D., will assume... Full story
Yahoo Finance • 15 days ago
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisiniclin... Full story
Yahoo Finance • 24 days ago
SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisiniclin... Full story
Yahoo Finance • last month
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT O... Full story
Yahoo Finance • 2 months ago
Achieve Life Sciences Inc (NASDAQ:ACHV [https://www.chartmill.com/stock/quote/ACHV/profile]) reported its second-quarter 2025 financial results, posting revenue of $0.0 and an earnings per share (EPS) loss of $0.37. These figures were larg... Full story
Yahoo Finance • 2 months ago
SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline... Full story
Yahoo Finance • 3 months ago
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund depreciated 12.4% net of fees in the quarter. The firm anticipates significant volatility... Full story
Yahoo Finance • 3 months ago
SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline... Full story
Yahoo Finance • 3 months ago
[Cigarette with prohibition sign on wooden table, top view. Quitting smoking concept] Liudmila Chernetska/iStock via Getty Images * Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]) said that it has named Omnico... Full story
Yahoo Finance • 3 months ago
Achieve Life Sciences (NASDAQ:ACHV [https://seekingalpha.com/symbol/ACHV]) has announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20150242-achieve-life-sciences-announces-pricing-of-45_0-million-underwrit... Full story
Yahoo Finance • 3 months ago
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline... Full story
Yahoo Finance • 3 months ago
SEATTLE/VANCOUVER - Achieve Life Sciences, Inc. (NASDAQ:ACHV) has appointed Omnicom (NYSE:OMC) as its strategic innovation partner and agency of record to support the planned U.S. commercial launch of cytisinicline, a treatment for nicotin... Full story
Yahoo Finance • 3 months ago
SEATTLE/VANCOUVER - Achieve Life Sciences, Inc. (NASDAQ:ACHV), a $120.7 million market cap pharmaceutical company whose stock has shown strong momentum with a 21% gain over the past week, announced Thursday a proposed underwritten public o... Full story
Yahoo Finance • 3 months ago
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline... Full story
Yahoo Finance • 3 months ago
Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to addre... Full story
Yahoo Finance • 3 months ago
Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in tw... Full story
Yahoo Finance • 4 months ago
SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline... Full story
Yahoo Finance • 4 months ago
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve... Full story